Skip to main navigation Skip to search Skip to main content

Early Closure of a Phase 1 Clinical Trial for SABR in Early-Stage Glottic Cancer

  • Byung Hee Kang
  • , T. Yu
  • , Jin Ho Kim
  • , Jong Min Park
  • , Jung In Kim
  • , Eun Jae Chung
  • , Seong Keun Kwon
  • , Ji Hoon Kim
  • , Hong Gyun Wu

Research output: Contribution to journal › Article › peer-review

41 Scopus citations

Abstract

Purpose: The early results of a phase 1 study of stereotactic ablative radiation therapy for early-stage glottis cancer were previously reported. However, additional late adverse events occurred in the second arm during the follow-up period. In this study, the dose-limiting toxicities and premature closure of the clinical trial are reported. Methods and Materials: Thirteen patients with cT1-2N0M0 squamous cell carcinoma of the glottis were enrolled between May 2015 and July 2018. Seven patients in the first arm received 59.5 Gy to the gross tumor volume and 47.6 Gy to the remaining larynx, delivered in 17 fractions. The second arm dose was 55 Gy and 40.7 Gy in 11 fractions to the gross tumor volume and the remaining larynx, respectively. Patients were treated according to the simultaneous integrated boost approach with volumetric modulated arc therapy. Results: The median follow-up was 37 months (range, 6-41.4) for the first arm and 14.5 months (range, 4.8-21.5) for the second arm. Maximum acute toxicity was grade 2 laryngeal mucositis for each arm. Maximum chronic toxicity was grade 3 laryngeal inflammation, occurring in 2 patients (33.3%) in the second arm. One patient underwent a laryngomicrosurgical biopsy for a vocal cord ulcer, and another patient underwent supraglottic laryngectomy because of arytenoid cartilage necrosis. In the first arm, chronic toxicity was not observed, except for grade 1 laryngeal edema in 1 patient. Conclusions: The phase 1 dose escalation study was terminated early because of the unexpected dose-limiting toxicities occurring in patients in the second arm. It was concluded that stereotactic ablative radiation therapy is not feasible for early-stage glottic cancer owing to treatment-related toxicity.

Original languageEnglish
Pages (from-to)104-109
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume105
Issue number1
DOIs
StatePublished - 1 Sep 2019

Bibliographical note

Publisher Copyright:
© 2019 Elsevier Inc.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Early Closure of a Phase 1 Clinical Trial for SABR in Early-Stage Glottic Cancer'. Together they form a unique fingerprint.

Cite this